On October 22, Guardant Health Inc. rose 5.01% in Regular Trading, trading near $170.785 per share, with turnover of $175 million.
The clearest catalyst was a recent patent appeal board decision rejecting Guardant Health Inc.'s challenge to all 30 claims of a US patent tied to duplex sequencing, preserving the patent's validity in a key dispute with TwinStrand Biosciences and the University of Washington.
That decision adds to an already material litigation backdrop. A final judgment issued in August maintained a prior willful infringement verdict, awarded more than $245.2 million in damages, accrued royalties and interest through May 31, and required Guardant Health Inc. to pay a 6% royalty on sales of 11 covered products and services from June 1 until patent expiry in March 2033, while also providing quarterly US sales accounting. The latest ruling therefore did not remove the legal burden; it confirmed that Guardant Health Inc.'s effort to invalidate a core patent claim set was unsuccessful.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments